Patent ID: 6552014
Filing Date: 2003-04-22
Classification: A61K,A61P

Abstract:
A method of reducing a platelet activation state of an individual comprising, administering to the individual an effective amount of at least one selective serotonin reuptake inhibitor (SSRI), wherein the SSRI prevents the reduction of serotonin in blood of the individual, and the SSRI is selected from the group consisting of venlafaxine, a venlafaxine metabolite, mirtazapine, a mirtazapine metabolite, buspirone, a buspirone metabolite, trazodone, a trazodone metabolite, nefazadone, a nefazadone metabolite, clomipramine, a clomipramine metabolite, imipramine, a imipramine metabolite, nortriptyline, a nortriptyline metabolite, mianserine, a mianserine metabolite, duloxetine, a duloxetine metabolite, dapoxetine, a dapoxetine metabolite, litoxetine, a litoxetine metabolite, femoxetine, a femoxetine metabolite, lofepramine, a lofepramine metabolite, tomoxetine, and a tomoxetine metabolite.